4 models fit Amrize Ltd Ordinary Shares and they agree: 4 of 4 land within 15% of the average.
Two or more of our models back this value.
Near fair value(i)Bronze51
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionAmrize Ltd Ordinary Shares (AMRZ)
Fair value (4 models)
$38.06
ACCE price target
$39.00
Rating
Fairly valued
Horizon
12 months
Fair value published on 20 Oct 2026, 16:04 CEST; previously $47.61 since 16 Oct 2026, 00:00 CEST.
ACCE price target published on 3 Oct 2026, 00:00 CEST.
Rating published on 20 Oct 2026, 16:04 CEST.
Price used: $39.44 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
3.6% above
-3.5% to fair value
ACCE score
55
out of 100
Analysts
50% buy
20 covering
P/E
18.0x
forward 13.4x
1-year return
-18.5%
Dividend yield
1.13%
Amrize Ltd Ordinary Shares in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Amrize makes cement, aggregates, ready-mix concrete and building products, mostly across North America, and it was spun out from the Holcim group, so the franchise is built on quarries, kilns and plants that are expensive and slow to replicate. Its structural edge is that aggregates and cement reserves near growing metro areas are hard to permit, which supports pricing power through the cycle. Revenue is growing 8.6% and operating margin sits at 20.5%, so the business is converting top-line growth into profit at a healthy rate. The shares trade at 13.4 times forward earnings against 17.0 times trailing, implying the market expects earnings to rise meaningfully over the next year. A score of 55/100 and a 9.7% return on equity suggest the quality case is only moderate, so the question for a portfolio manager is whether the forward earnings step-up holds up under scrutiny.